

ÖNER SÜZER <osuzer@istanbul.edu.tr>

02/19/16 at 12:58 PM

To Bahar Tunctan, metiner.tosun@ege.edu.tr, serinmss@yahoo.com

CC EPHAR2016

Dear colleague,

We have published the time course of main sessions at <http://www.ephar2016.org/?p=program>. Your main session entitled “**Targeting coding and non-coding RNAs in pharmacological research**” is scheduled on Monday, the 27th of June 2016 between 09:00 and 12:00. The current structure of the session is provided below.

We kindly request you to upload the abstract of your speech no later than Wednesday the 25th of May, 2016 using the link below

[http://www.abstractmodule.com/v04/spktext\\_upload.asp?pdir=2016ephar&plng=eng](http://www.abstractmodule.com/v04/spktext_upload.asp?pdir=2016ephar&plng=eng).

If the title of your speech is different from the one we provide in the preliminary program, the title will be changed according to your uploaded file.

If you are a chairman but you do not have a speech in the program, uploading an abstract is optional, however if you intend to make a brief definition of the panel, you can also upload this text.

Please do not hesitate to contact me in case you have any questions. I look forward to meeting you in Istanbul.

Warm regards

Öner Süzer, MD, Prof.

Congress Chair EPHAR2016

### **Panel Structure**

#### **Targeting coding and non-coding RNAs in pharmacological research**

Sponsor: Turkish Pharmacological Society

Chairman / Cochair: Bahar TUNÇTAN

Targeting miRNAs in the treatment of cardiovascular and renal diseases

Bahar TUNÇTAN, Mersin University, TURKEY

Targeting the store-operated calcium entry

Metiner TOSUN, Ege University, TURKEY

miRNAs as biomarkers for early diagnosis of certain diseases

Mehmet Sami SERİN, Mersin University, TURKEY

--

Öner Süzer, MD, Prof.

University of Istanbul

Cerrahpasa Faculty of Medicine

Department of Medical Pharmacology

34303, Kocamustafapasa/Istanbul, Turkey

Phone & Fax: +90 212 4143023

E-mail: [osuzer@istanbul.edu.tr](mailto:osuzer@istanbul.edu.tr)

URL: [www.onersuzer.com](http://www.onersuzer.com)



## 7<sup>th</sup> European Congress of Pharmacology



### EPHAR2016

Military Museum and Cultural Center  
June 26-30 2016, İstanbul, TURKEY  
[www.ephar2016.org](http://www.ephar2016.org)



## Speakers

- Gül Güner AKDOĞAN, İzmir University of Economics, TURKEY
- Feyza ARICIOĞLU, Marmara University, TURKEY
- Damian BELL, Charles River Laboratories, UK
- David BISHOP-BAILEY University of London, UK
- Juan CANALES, University of Leicester, UK
- Gerard BANNENBERG, Global Organization for EPA and DHA omega3s, USA
- Philip CALDER, University of Southampton, UK
- Steven CARLTON, The University of Nottingham, UK
- Giuseppe CIRINO, University of Naples, ITALY
- Stefanie DIMMELER, Goethe-University Frankfurt am Main, GERMANY
- Lucy DONALDSON, University of Nottingham, UK
- Filippo DRAGO, University of Catania, ITALY
- Nezahat Tugba DURLU-KANDİLCİ, Hacettepe University, TURKEY
- Nurhan ENGİNAR, İstanbul University, TURKEY
- Julio GÁLVEZ, University of Granada, SPAIN
- Nikita GAMPER, University of Leeds, UK
- Ece GENÇ, Yeditepe University, TURKEY
- Johan GARSSEN, Utrecht University, The NETHERLANDS
- Zafer GÖREN, Marmara University, TURKEY
- Thomas GRIESBACHER, Medizinische Universität Graz, AUSTRIA
- Bert 'T HART, Biomedical Primate Research Centre, The NETHERLANDS
- Jaap Van HARTEN, Elsevier BV, The NETHERLANDS
- Oliver HAWORTH, Barts and the London School of Medicine & Dentistry, UK
- Doris HÖGLINGER, University of Oxford, UK
- Zsuzsanna HELYES, University of Pecs, HUNGARY
- Peter ILLES, Universität Leipzig, GERMANY
- Halil KAVAKLI, Koç University, TURKEY
- Aletta KRANEVELD, Utrecht University, The NETHERLANDS
- Zdravko LACKOVIC, University of Zagreb, CROATIA
- Francis LEVI, Warwick University, UK
- Francesca LEVI-SCHAFFER, The Hebrew University of Jerusalem, ISRAEL
- Juan-Carlos LEZA, Complutense University of Madrid, SPAIN
- Qian LI, Harvard Medical School, USA
- Martin LÖHSE, University of Würzburg, GERMANY
- Claus Juul LOLAND, Copenhagen University, DENMARK
- Maria-Isabel LOZA, University of Santiago de Compostela, SPAIN
- Michael John Mulvany, Aarhus University, DENMARK
- Ali MODERRİSOĞLU, Sifar Pharmaceuticals, TURKEY
- Özgür ÖKTEM, Koç University, TURKEY
- Alper OKYAR, İstanbul University, TURKEY
- Hakan Sedat Ozer, Koç University, TURKEY
- Nuri ÖZTÜRK, Gebze Technical University, TURKEY
- Andreas PAPAPETROPOULOS, University of Athens, GREECE

- Gérard A. Rongen, Radboud University, The NETHERLANDS
- Mercè ROQUÉ, Hospital Clínic de Barcelona, SPAIN
- Maria-Jesus SANZ, University of Valencia, SPAIN
- Martina SCHMIDT, University of Groningen, THE NETHERLANDS
- Mehmet Sami SERİN, Mersin University, TURKEY
- Sena SEZEN, Karadeniz Technical University, TURKEY
- Ulf SIMONSEN, Aarhus University, DENMARK
- Harald SITTE, Medical University of Vienna, AUSTRIA
- Beata SPERLAGH, Hungarian Academy of Sciences, HUNGARY
- Clare STANFORD, University College London, UK
- Gary STEPHENS, University of Reading, UK
- Edward STEVENS, Pfizer Neuroscience and Pain Research Unit, UK
- Öner SÜZER, İstanbul University, TURKEY
- Csaba SZABO, The University of Texas Medical Branch, USA
- Juan TAMARGO, Complutense University of Madrid, SPAIN
- Gökçe TOPAL, İstanbul University, TURKEY
- Metiner TOSUN, İzmir University of Economics, TURKEY
- Bahar TUNÇTAN, Mersin University, TURKEY
- B. Sönmez UYDEŞ DOĞAN, İstanbul University, TURKEY
- Clemens VON SCHACKY, University of Munich, GERMANY
- Johan Van de VOORDE, Ghent University, BELGIUM
- John L. WALLACE, Antibe Therapeutics, CANADA
- Matthew WHITEMAN, University of Exeter, UK
- Rob WINWOOD, DSM Nutritional Products, SWITZERLAND
- David P. WOLDBYE, Copenhagen University, DENMARK
- Günay YETİK ANACAK, Ege University, TURKEY

## **Hall D: Targeting coding and non-coding RNAs in pharmacological research**

(Organized by Turkish Pharmacological Society)

Organizers and chairs:

Bahar Tunçtan (Mersin University Faculty of Pharmacy Department of Pharmacology)

09:00-12:00

- 09:00 Targeting miRNAs in the treatment of cardiovascular and renal diseases  
Bahar Tunçtan  
Mersin University, TURKEY
- 09:30 Targeting the store-operated calcium entry  
Metiner Tosun  
İzmir University of Economics, TURKEY
- 10:00 miRNAs as biomarkers for early diagnosis of certain diseases  
Mehmet Sami Serin  
Mersin University, TURKEY
- 10:30 Coffee break
- 11:00 Elevated talk (C009): The effect of S-nitrosoglutathione (GSNO) in a rat model of isoproterenol induced myocardial infarction  
Deniz Kaleli Durman  
İstanbul University, TURKEY  
(Authors: Deniz Kaleli Durman, Uğur Aksu, Duygu Terzioğlu, Işık İkbal Barış, Dilek Yılmaz Bayhan, Birsal Sönmez Uydeş Doğan)
- 11:15 Elevated talk (C010): Protective and therapeutic effects of doxycycline against renal ischemia-reperfusion injury in rats  
Mustafa Sağır  
Gaziosmanpaşa University, TURKEY  
(Authors: Mustafa Sağır, Hakan Parlakpınar, Fatih Oguz, Alaaddin Polat, Gul Pelin Odabasi)
- 11:30 Elevated talk (C011): PYK2 as a therapeutic target for myocardial infarction  
Sofia Iris Bibli  
National and Kapodistrian University of Athens, GREECE  
(Authors: Sofia Iris Bibli, Zongmin Zhou, Sven Zukunft, Beate Fisslthaler, Ioanna Andreadou, Csaba Szabo, Peter Brouckaert, Ingrid Fleming, Andreas Papapetropoulos)
- 11:45 Elevated talk (C012): The effect of beta 3-ARs on Na<sup>+</sup>/K<sup>+</sup>-ATPase in cardiac hypertrophy  
Gizem Kayki Mutlu  
Ankara University, TURKEY  
(Authors: Gizem Kayki Mutlu, Ebru Arioglu Inan, Irem Karaomerlioglu, Vecdi Melih Altan)
- 12:00 End of symposium

### **miRNAs as biomarkers for early diagnosis of certain diseases**

**Mehmet Sami Serin**

Mersin University Faculty of Pharmacy, Department of Pharmaceutical Microbiology,  
TURKEY

MicroRNAs (miRNAs) are a class of short non-coding RNA molecules. They have attracted significant attention from biomedical research communities over the past two decades. Facilitated by high-throughput genomics and bioinformatics in conjunction with traditional molecular biology techniques and animal models, miRNA research is now positioned to make the transition from laboratories to clinics to deliver profound benefits to public health.

MicroRNAs (miRNAs) are small, however important regulators of post-transcriptional gene expression that have been linked to various cellular processes. Alterations of miRNAs are associated with a number of disease pathologies. With over 5000 miRNAs discovered in humans to date, many of them have already been implicated in common human disorders such as cancer, viral diseases, immune-related diseases, Neurodegenerative diseases. miRNAs have important potential to becoming the next generation of diagnostics and therapeutics.

Biomarker potential of several miRNAs for the early diagnosis of hepatocellular carcinoma related with HBV and HCV infections will be focused in this presentation.